Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17413477 | 0.79 | PNMT (1.00) | PNMTSLC6A2SLC6A3SLC6A4TAAR1 | |
| SCHEMBL3058411 | 0.79 | PNMT (1.00) | PNMTSLC6A2SLC6A3SLC6A4TAAR1 | |
| SCHEMBL3058413 | 0.79 | PNMT (1.00) | PNMTSLC6A2SLC6A3SLC6A4TAAR1 | |
| SCHEMBL10599864 | 0.79 | PNMT (0.51) | PNMTSIGMAR1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8369404 | 0.76 | PNMT (0.61) | PNMTSIGMAR1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8369405 | 0.76 | PNMT (0.61) | PNMTSIGMAR1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8582269 | 0.75 | PNMT (0.47) | PNMTSIGMAR1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8581618 | 0.75 | PNMT (0.47) | PNMTSIGMAR1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL17407613 | 0.73 | PNMT (0.72) | PNMTSIGMAR1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8105515 | 0.73 | PNMT (0.45) | PNMTSIGMAR1SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293745-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293745-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | PNMT 3149/4885SIGMAR1 636/4885SLC6A2 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.